(Medical Xpress)—Scientists have identified 46 previously overlooked but potentially 'druggable' cancer targets, using a powerful new online approach that allows researchers to carry out 'virtual experiments' to quickly ...
Jan 2, 2013
0
0
A new study has created the most comprehensive analysis for understanding how cancer drugs work at a molecular level. Scientists at the Wellcome Sanger Institute, EMBL's European Bioinformatics Institute (EMBL-EBI) and AstraZeneca ...
Jul 7, 2020
0
163
Thousands of rare diseases cumulatively affect millions of people across the globe, yet because each case is so rare doctors struggle to accurately diagnose and effectively treat individual patients. Every time a patient ...
Nov 26, 2019
0
73
Lagging behind in launching new medicines means a much smaller market share for pharmaceutical companies—even if they spend just as much on advertising, according to new research from Duke University's Fuqua School of Business.
Sep 4, 2015
0
7
eTRANSAFE, the European project to share data on the safety of medicines, has come to fruition. On a single platform, the project has integrated data from more than 10,000 pharmacological studies by reference pharmaceutical ...
Jun 30, 2023
0
17
Medications currently used to treat multiple sclerosis (MS) can merely reduce relapses during the initial relapsing-remitting phase. Many patients, however, develop progressive MS at a later stage, with disability becoming ...
Aug 20, 2019
0
4
Drug R&D costs have increased substantially in recent decades, while the number of new drugs has remained fairly constant, leading to concerns about the sustainability of drug R&D and question about the factors that could ...
Feb 27, 2015
0
4
In a recently published article in Nature Reviews Drug Discovery, Professor Yihai Cao's research group at the Department of Microbiology, Tumor and Cell Biology, charts information about drug development for the treatment ...
Apr 14, 2023
0
2
The regulatory requirements for the approval of new drugs vary greatly internationally in regards to the resources allocated to the authorities, the evaluation periods for approval and the fees for the pharmaceutical companies. ...
Aug 14, 2017
0
1
(Medical Xpress)—Paying too much heed to possible risks when licensing a medication can lead to a pharmaceutical of great benefit to patients either not being licensed or else having its use restricted. For this reason, ...
Dec 3, 2013
0
0
